AbbVie
-
AbbVie solidifies immunology dominance with US$10.9B cash acquisition of Apogee
The acquisition ranks among AbbVie’s largest transactions in recent years and reflects the company’s strategy to expand its next-generation immunology medicines as competition intensifies across the sector.
-
AbbVie seeks EU approval to expand MAVIRET use for acute Hepatitis C treatment
If approved, MAVIRET would become one of the few therapies in the European Union indicated for both acute and chronic HCV infection.
-
AbbVie announces USD$1.4B manufacturing campus in North Carolina
The Illinois-based drugmaker said the new campus will span 185 acres near Research Triangle Park, one of the country’s leading life sciences clusters.
-
AbbVie inks USD735M deal with Haisco for non-opioid NaV1.8 painkillers
The company receives USD10 million in near-term milestones and stands to earn up to USD 705 million additional milestone payments upon reaching key development and regulatory benchmarks.
-
AbbVie invests USD380M in Illinois manufacturing facilities to increase API production
AbbVie plans to hire 300 new employees for the facilities, targeting engineers, scientists, manufacturing operators, and lab technicians in the North Chicago area.